OXB.L vs TMO
OXB.L: A leader in the viral vector manufacturing sector, providing essential development and production services for advanced cell and gene therapy treatments. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | OXB.L | TMO | Edge |
|---|---|---|---|
| Price as of 2026-08-03 close | £5.61 | $577.83 | |
| Market cap as of 2026-08-06 | n/a | $213.7B | |
| P/E as of 2026-08-06 | n/a | 30.64 | |
| PEG as of 2026-08-06 | n/a | 3.39 | |
| Net margin as of 2026-08-06 | n/a | +15.0% | |
| Gross margin as of 2026-08-06 | n/a | +40.9% | |
| Operating margin as of 2026-08-06 | n/a | +17.6% | |
| ROE as of 2026-08-06 | n/a | +13.3% | |
| ROA as of 2026-08-06 | n/a | +6.3% | |
| Debt / equity as of 2026-08-06 | n/a | 0.81 | |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +7.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.3% | |
| Dividend yield as of 2026-08-06 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-06 | n/a | 0.88 | |
| 1-year return as of 2026-08-03 close | +20.8% | +23.9% | TMO higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.